Your web browser is out of date.
For your security and improved experience online, please update your browser.
Trulicity is indicated for the treatment of adults with
insufficiently controlled type 2 diabetes mellitus as an
adjunct to diet and exercise:
Adverse event reporting information can be found at the bottom of the page.
Not registered? Register now
Trulicity (dulaglutide) is a once weekly injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) with proven efficacy in reducing HbA1c in adults with type 2 diabetes.1 The REWIND study demonstrated cardiovascular benefits for Trulicity reducing the risk of major cardiovascular events, in a broad type 2 diabetes population.2
This live webinar will take place on 10 September 2021 at 13:00. The session faculty will consist of Dr Shahzada Khan (Chair) and the key-note speaker Dr Akhila Mallipedhi. Dr Mallipedhi will consider the clinical trial data supporting Trulicity (dulaglutide) in treating people with type 2 diabetes2 and examine the practicalities of initiating this medication in the same population. There will also be a look at the Trulicity (dulaglutide) higher dose data provided by the AWARD-11 trial3. Throughout the webinar there will be ample opportunity to submit questions to be answered during the live Q&A following the broadcast.
GP Principle, Newham, East London
Consultant in Diabetes, Prince Phillip Hospital, Llanelli
Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store, or Ireland: www.hpra.ie. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000, or Lilly Ireland on 01 664 0446.
Sign up to all DiabetesontheNet journals
This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.